ADE LLC’s Charles River Laboratories CRL Stock Holding History

ADE LLC’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$83K	–	112
2021 Q3	$83K	Hold	200	–	–	0.08%	102
2021 Q2	$74K	Buy	+200	New	+$66.8K	0.07%	112

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ADE LLC's CRL Position: Q4 2021 in Review

ADE LLC sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 200 shares — an estimated $83K sold.

ADE LLC first reported a position in CRL in Q2 2021 and held it in 2 quarters. The position peaked at $83K in Q3 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

ADE LLC reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
ADE LLC sold 200 Charles River Laboratories shares in Q4 2021, an estimated $83K.
ADE LLC first reported a position in Charles River Laboratories in Q2 2021 and held it in 2 quarters.
ADE LLC's Charles River Laboratories position peaked at $83K in Q3 2021.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on ADE LLC's 13F filing for Q4 2021, filed 14 Feb 2022.